Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Fibromyalgia is a chronic condition characterized by pain and tenderness. The primary goal of treatment is to reduce pain, and there are multiple well-established treatment options available, many of which are generic. Even though the majority of the diagnosed fibromyalgia population receives prescription drug treatment, most current therapies suffer from shortcomings in efficacy. The substantial percentage of patients with inadequate pain relief, the need for improved treatment of the secondary symptoms of fibromyalgia (e.g., anxiety, major depressive disorder, fatigue), and other areas with large unmet need (e.g., drugs that restore neuronal function)together pose ample commercial opportunity for new drugs that improve fibromyalgia treatment.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 30 European rheumatologists fielded in January 2019.
Key companies: Allergan, Boehringer Ingelheim, Eli Lilly, Grünenthal, Janssen, Neuraxpharm, Pfizer, Pierre Fabre.
Key drugs: Duloxetine (Cymbalta/Xeristar, generics), gabapentin (Neurontin, generics), pregabalin (Lyrica, generics), milnacipran (Savella/Ixel, generics), tramadol (Ultram/Topalgic/Contramal/Tramal/Tramacet/Zydol, other brands, generics), amitriptyline, and cyclobenzaprine.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Already a Client? Log in to access this report.
Audreza Das is a Senior Analyst in the CNS/Ophthalmology team at Decision Resources Group She has authored content across indications, including neuropathic pain, age-related macular degeneration, treatment-related depression, painful diabetic neuropathy, and migraine. Ms. Das has previously worked at Novo Nordisk, as a Market Analyst for European markets. Previous experience at a SME, included developing disease competitive landscapes, covering global conferences etc. Ms. Das received her degree in Biotechnology from Birla Institute of Technology, a deemed university and her Diploma in Cancer Immunology & Biotechnology from University of Nottingham.